Does hormonal contraception increase the risk for tumors?;Erhöht die hormonale kontrazeption das tumorrisiko?

Therapeutische Umschau

Volumn 66, Issue 2, 2009, Pages 129-135

  Braendle, Wilhelm ^a   Kuhl, Herbert ^b   Mueck, Alfred ^c   Birkhäuser, Martin ^d   Thaler, Christian ^e   Kiesel, Ludwig ^f   Neulen, Joseph ^g  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENIGN TUMOR; BREAST CARCINOMA; BREAST TUMOR; CANCER RISK; COLORECTAL CARCINOMA; DRUG USE; ENDOMETRIOSIS; ENDOMETRIUM CANCER; HORMONAL CONTRACEPTION; LIVER CELL; MELANOMA; MYOMA; NODULAR HYPERPLASIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEXUAL BEHAVIOR; UTERINE CERVIX CARCINOMA; UTERUS MYOMA; VAGINA CARCINOMA; VULVA CARCINOMA;

ADULT; AGE FACTORS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; LONG-TERM CARE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; YOUNG ADULT;

EID: 59849103650     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.66.2.129     Document Type: Review

References (47)

1. Aseni P, Sansalone CV, Sammartino C, Benedetto FD, Carrafiello G, Giacomoni A, Osio C, Vertemati M, Forti D. Rapid disappearance of hepatic adenoma after contraceptive withdrawal. J Clin Gastroenterol 2001; 33: 234-6.
2. Brinton LA, Vessey MP, Flavel R, Yates D. Risk factors for benign breast disease. Am J Epidemiol 1981; 113: 203-14.
3. Broome M, Clayton J, Fotherby K. Enlarged follicles in women using oral contraceptives. Contraception 1995; 52: 13-6.
4. Chiaffarino F, Parazzini F, LaVecchia C, Marsico S, Surace M, Ricci E. Use of oral contraceptives and uterine fibroids: results from a case control study. Br J Obstet Gynaecol 1999; 106: 857-60.
5. Christensen JT, Boldsen JL, Westergaard JG. Functional ovarian cysts in premenopausal and gynecological healthy women. Contraception 2002; 66: 153-7.
6. Cobey FC, Salem RR. A review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. Am J Surg 2004; 187: 181-91.
7. Gateley CA, Bundred NJ, West RR, Mansel RE. A case control study of factors associated withmacroscopic breast cysts. Eur J Cancer 1992; 28: 125-7.
8. Holt VL, Cushing-Haugen Kl, Daling FR. Oral contraceptives, tubal sterilization, and functional ovarian cyst risk. Obstet Gynecol 2003; 102: 252-8.
9. Mayol X, Neal GE, Davies R, Romero A, Domingo J. Ethinyl estradiol-induced cell proliferation in rat liver. Involvement of specific populations of hepatocytes. Carcinogenesis 1992; 13: 2381-8.
10. Mays ET, Christopherson WM, Williams HC, Mahr MM. A few women taking the pill found to have benign liver tumors. JAMA 1975; 321: 451-2.
11. Mettlin C, Natarajan N. Studies on the role of oral contraceptive use in the etiology of benign and malignant liver tumors. J Surg Oncol 1981; 18: 73-85.
12. Pain JA, Ginson AE, Williams R, Howard ER. Focal nodular hyperplasia of the liver: results of treatment and options in management. Gut 1991; 32: 524-7.
13. Parazzini F, La Vecchia C, Franceschi S, Decarli A, Gallus G, Regallo M, Liberati A, Tognoni G. Risk factors for pathologically confirmed benign breast disease. Am J Epidemiol 1984; 120: 115-22.
14. Parazzini F, Di Cintio E, Chatenoud L, Moroni S, Ardovino I, Struzziero E, Falsetti L, Bianchi A, Bracco G, Pellegrini A, Bertulessi C, Romanini C, Zupi E, Massobrio M, Guidetti D, Troiano L, Beretta P, Franchi M. Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial. Gruppo Italiano per lo Studio dell'Endometriosi. Eur J Obstet Gynecol Reprod Biol 2000; 88: 11-4.
15. Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. Drugs 2004; 64: 2447-62.
16. Vessey M, Yeates D. Oral contraceptives and benign breast disease: an update of findings in a large cohort study. Contraception 2007; 76: 418-24.
17. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F. WHO International Agency for Research on Cancer Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005; 6: 552-3.
18. Thomas DB. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives: the influence of combined oral contraceptives on risk of neoplasms in developing and developed countries. Contraception 1991; 43: 695-710.
19. Hannaford PHC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007; 335: 651-8.
20. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-27.
21. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. The New England Journal of Medicine 2002; 346: 2025-32.
22. Silvera SA, Miller AB, Rohan TE. Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. Cancer Causes Control 2005; 16: 1059-63.
23. Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, Andrulis IL, West DW, Li FP, Southey MC, Giles GG, McCredie MR, Hopper JL, Whittemore AS. Oral contraceptive use and risk of early-onset breast cancer in carriers and non-carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2005; 14: 350-6.
24. Bertram CC. Evidence for practice: oral contraception and risk of cervical cancer. J Am Acad Nurse Pract 2004; 16: 455-61.
25. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004; 190: 5-22.
26. Irwin KL. The association between oral contraceptive us and neoplasia of the cervix, vagina and vulva. In: Evidence-Guided Prescribing of the Pill (Hannaford and Webb eds.). Parthenon Publishing Group UK 1996: 145-56.
27. Morene V, Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papilloma-virus infectkion: the IARC multicentric case-control study. Lancet 2002; 359: 1085-92.
28. Smith JS, Green J, Barrington de Gonzalez A, Appleby P, Peto J, Plummer M, Francheschi, Beral V. Cervical Cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361: 1159-67.
29. Smith JS, Bosetti C, Munoz N, Herrero R, Bosch FX, Eluf-Neto J, Meijer CJ, Van Den Brule AJ, Franceschi S, Peeling RW. IARC multicentric case-control study. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004; 111: 431-9.
30. Epstein RJ. Primary prevention of human papillomavirus-dependent neoplasia: no condom, no sex. Eur J Cancer 2005; 41: 2595-600.
31. International collaboration of epidemiological studies of cervical cancer. Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13 541 women with carcinoma of the cervix and 23 017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006; 118: 1481-95.
32. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004; 190: 5-22.
33. Franceschi S. Oral contraceptive use and risk of cancer of the ovary and corpus uteri. In: Evidence-Guided Prescribing of the Pill (Hannaford and Webb eds.). Parthenon Publishing Group UK, 1996: 135-44.
34. Schildkraut JM, Calingaertz B, Marchbanks PA, et al. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J of the National Cancer Institute 2002; 94: 32-38.
35. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002, 155: 217-24.
36. Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, Andrulis IL, West DW, Li FP, Southey MC, Giles GG, McCredie MR, Hopper JL, Whittemore AS. Oral contraceptive use and risk of early-onset breast cancer in carriers and non-carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2005; 14: 350-6.
37. Deligeoroglou E, Michailidis E, Creatsas G. Oral contraceptives and reproductive system cancer. Ann N Y Acad Sci 2003; 997: 199-208.
38. ESHRE Capri Workshop Group. Ovarian and endometrial function during hormonal contraception. Hum Reprod 2001; 16: 1527-35.
39. Palmer JR, Rosenberg L, Strom BL, Harlap S, Zauber AG, Warshauer ME, Shapiro S. Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control 1992; 3: 547-54.
40. Scalori A, Tavani A, Gallus S, La Vecchia C, Colombo M. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study. Am J Obstet Gynecol 2002; 186: 195-7.
41. Brambilla G, Martelli A. Are some progestins genotoxic liver carcinogens? Mutat Res 2002; 512: 155-63.
42. Yu MW, Chang HC, Chang SC, Liaw YF, Lin SM, Liu CJ, Lee SD, Lin CL, Chen PJ, Lin SC, Chen CJ. Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. Hepatology 2003; 38: 1393-400.
43. Yu MC, Yuan JM, Govindarajan S, Ross RK. Epidemiology of hepatocellular carcinoma. Can J Gastroenterol 2000; 14: 703-9.
44. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004; 127 (Suppl 1): S72-S78.
45. Bosch FX, Ribes J. Epidemiology of liver cancer in Europe. Can J Gastroenterol 2000; 14: 621-30.
46. Libbrecht L, Craninx M, Nevens F, Desmet V, Roskams T. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 2001; 39: 66-73.
47. Lam CM, Yong JL, Chan AO, Ng KK, Poon RT, Liu CL, Lo CM, Fan ST. Better survival in female patients with hepatocellular carcinoma: oral contraceptive pills related? J Clin Gastroenterol 2005; 39: 533-9.